Sysmex (SSMXY) Stock Price, News & Analysis

Company Overview

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis. In coagulation testing, Sysmex provides instruments and reagents to assess blood‐clotting function and monitor anticoagulant therapy. Its urine analyzers combine digital imaging with automated particle analysis, while immunochemistry systems enable quantitative measurement of biomarkers for infectious disease, hemostasis and diabetes monitoring.

Sysmex maintains a global footprint with regional headquarters and sales subsidiaries in North America, Europe, Asia‐Pacific, Latin America and Africa. Its products and services reach more than 150 countries, supported by local service networks that offer training, maintenance and technical support. The company collaborates with academic and industrial partners to develop molecular diagnostic assays and next‐generation testing platforms, positioning itself at the forefront of personalized medicine and digital health solutions.

Founded in 1968, Sysmex has grown through continuous investment in research and development. The company is led by President and Chief Executive Officer Yutaka Yamada, supported by an executive team focused on innovation, quality and international expansion. Over its history, Sysmex has earned a reputation for reliability and precision in clinical diagnostics, driving efforts to improve patient care and laboratory efficiency worldwide.

Key Stats

• Today's Range: $12.38 to $12.51
• 50-Day Range: $8.37 to $12.58
• 52-Week Range: $8.01 to $13.49
• Volume: 12,681 shs
• Average Volume: 33,411 shs
• Market Capitalization: $7.82 billion
• P/E Ratio: 29.57
• Dividend Yield: 1.13%
• Price Target: N/A
• Consensus Rating: Hold

Sysmex Stock Analysis - MarketRank™

Sysmex scored higher than 84% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Sysmex has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sysmex has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 34.21%

Earnings Growth

Earnings for Sysmex are expected to grow by 34.21% in the coming year, from $0.38 to $0.51 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sysmex is 29.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.63.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sysmex is 29.57, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 270.69.

Price to Book Value per Share Ratio

Sysmex has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.05% of the float of Sysmex has been sold short.

Short Interest Ratio / Days to Cover

Sysmex has a short interest ratio ("days to cover") of 2.88, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sysmex has recently decreased by 9.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Sysmex pays a meaningful dividend of 1.17%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Sysmex does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sysmex is 33.33%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Sysmex will have a dividend payout ratio of 27.45% next year. This indicates that Sysmex will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Sysmex has a news sentiment score of 2.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Sysmex this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sysmex insiders have not sold or bought any company stock.

Percentage Held by Institutions

Sysmex has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 8/21/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: OTCMKTS:SSMXY
• CIK: 1517231
• Web: www.sysmex.co.jp
• Phone: (178) 265-0500
• Fax: 817-8265-0524
• Employees: 11,457
• Year Founded: 1968

Profitability

• EPS (Trailing Twelve Months): $0.42
• Trailing P/E Ratio: 29.57
• Forward P/E Ratio: 32.68
• P/E Growth: N/A
• Net Income: $234.01 million
• Net Margins: 7.62%
• Pretax Margin: 9.81%
• Return on Equity: 7.87%
• Return on Assets: 5.65%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 3.26
• Quick Ratio: 2.46

Sales & Book Value

• Annual Sales: $3.32 billion
• Price / Sales: 2.35
• Cash Flow: $0.90 per share
• Price / Cash Flow: 13.84
• Book Value: $5.30 per share
• Price / Book: 2.34

Miscellaneous

• Outstanding Shares: 629,480,000
• Free Float: N/A
• Market Cap: $7.82 billion
• Optionable: Not Optionable
• Beta: 1.05